Pionyr Immunotherapeutics

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a San Francisco-based biotechnology company and developer of cancer immunotherapies designed to target the tumor microenvironment.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Pionyr Immunotherapeutics funding round, December 2017
62,000,000
December 2017
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
June 23, 2020
FierceBiotech
As it continues with its small to medium-sized biotech deals, Gilead has put down $275 million for a 49.9% share in immuno-oncology biotech Pionyr with the option to buy it out completely should it pass muster in early clinical tests.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.